Gerontology: collagen disease

Effects of aging and postmenopausal hypoestrogenism on skin elasticity and bone mineral density in Japanese women

Skin collagen content and bone mass decrease with aging. Loss of collagen from the skin might decrease its elasticity. We investigated associations between skin elasticity, bone mineral density (BMD), age, and menopausal hypoestrogenism. Thirty-eight healthy Japanese postmenopausal women were studied (mean age, 55.7 +/- 5.9 yr; range, 48 to 71). Skin elasticity was measured using a suction device applied to the dorsal right forearm. BMD values of L2 to 4 vertebral bodies were measured by dual-energy X-ray absorptiometry. Age showed significant negative correlations with both skin elasticity and BMD (r = -0.57, p<0.001 and r = -0.40, p<0.05, respectively). Years since menopause also showed significant negative correlations with both skin elasticity and BMD (r = -0.51, p<0.01 and r = -0.41, p<0.05, respectively). We also found a positive correlation between skin elasticity and BMD in these postmenopausal women (r = 0.44, p<0.01). In conclusion, we demonstrated declining skin elasticity and bone mass in postmenopausal women to possibly be age- and estrogen-related. Additionally, decreased skin elasticity might serve as a predictor of bone loss in postmenopausal women.

Increased reduction in bone density and skin thickness in postmenopausal women taking long-term corticosteroid therapy: a suggested role for estrogen add-back therapy

BACKGROUND

Long-term corticosteroid therapy is complicated by osteoporosis and generalized thinning of the skin. These two complications of such therapy were routinely assessed at the Menopause Clinic of St. Luke's Hospital Medical School, University of Malta.

METHODS

A cross-sectional study was performed on 64 postmenopausal women who had been taking long-term corticosteroids. Each woman had her skin thickness measured using high-resolution ultrasound (22 MHz) and her bone density measured by dual-energy X-ray absorptiometry (DEXA). These measurements were compared with those of a control group (n = 557), a group of women who had sustained osteoporotic fractures (n = 180) and a group of women taking hormone replacement therapy (HRT) (n = 399). A longitudinal study of 29 postmenopausal women taking corticosteroids was also performed. This study compared results for women who, in addition to their corticosteroids, were taking HRT and for those who were taking corticosteroids alone.

RESULTS

The cross-sectional study showed that corticosteroid therapy was associated with the lowest mean skin thickness measurement (0.83 mm). Similarly, low mean bone density measurements for the lumbar spine (0.805 g/cm2) and left hip (0.715 g/cm2) were obtained for this group. The mean skin thicknesses in the control group and the HRT group were 0.93 mm and 0.935 mm, respectively, while that in the osteoporotic fracture group was 0.88 mm. The bone density of the fracture group was similar to that of the group of women taking long-term corticosteroids, with the lumbar spine having a mean density of 0.805 g/cm2 and 0.81 g/cm2, and the left hip having a density of 0.705 g/cm2 and 0.715 g/cm2, respectively. Bone densities were similar for the control group and the HRT group, and higher than that of the corticosteroid or fracture group. The lumbar spine had a mean density of 0.925 g/cm2 in the control group and 0.93 g/cm2 in the hormonally treated group. Both the treated and control groups had similar bone densities of the left hip at about 0.82 g/cm2. The small longitudinal study compared postmenopausal women on long-term corticosteroid therapy taking HRT with another group who were not taking HRT. This 4-year study revealed mean total increases in skin thickness of 6.1% and bone density of 5.5% (left hip) and 14.6% (lumbar spine) in the HRT group, since the start of the study. Conversely, the control group registered reductions over 4 years in both skin thickness (2.8%) and bone density (lumbar spine 4.5% and hip 5.0%).

CONCLUSION

In postmenopausal women taking long-term corticosteroids, skin thickness and bone density were both decreased, but the addition of HRT as add-back improved the situation dramatically. Skin thickness and bone density in women taking long-term corticosteroids were comparable to those in women who had sustained osteoporotic fractures. It is therefore suggested that HRT be used as add-back therapy in postmenopausal women taking long-term corticosteroid therapy.

Increased Reduction in Bone Density and Skin Thickness in Postmenopausal Women on Long Term Corticosteroid Therapy

BACKGROUND

Long term steroid therapy is complicated by osteoporosis and generalised thinning of the skin. These two complications of long term corticosteroid therapy were routinely assessed at the Menopause Clinic of St. Luke's Hospital, Medical School, University of Malta.

METHODS

A cross sectional study was performed on 64 postmenopausal women who had been on long term corticosteroids. Each woman had her skin thickness measured using high resolution ultrasound (22 mhz) and their bone density measured using a DEXA Norland. These measurements were compared to a control group (n = 557), a group of women who had sustained osteoporotic fractures (n = 180), and a group of women on hormone replacement therapy (HRT) (n = 399). A longitudinal study on 29 postmenopausal women on corticosteroids was also performed. In this study results were compared between women who in addition to their corticosteroids were on HRT and those who were on corticosteroids alone.

RESULTS

The cross sectional study showed the corticosteroid therapy was associated with the thinnest skin thickness measurements mean 0.83 mm. Similarly, low bone density measurements lumbar spine mean 0.81 g/cm2 and left hip mean 0.71 g/cm2 were obtained for this group. The skin thickness in controls and in the HRT groups had a mean thickness of 0.93 mm while that of the osteoporotic fracture group was 0.88 mm. The bone density of the osteoporotic fractures in the fracture group was similar to that of group of women on long term corticosteroids. The lumbar spine had a mean density of 0.81 g/cm2 and left hip that of 0.71 g/cm2. The bone density of the control group and HRT group was significantly higher. The lumbar spine had a mean density of 0.93 g/cm2 and that of left hip was 0.82 g/cm2. The small longitudinal study compared postmenopausal women on long term corticosteroid therapy on HRT to another group who was not on HRT. The longitudinal study over four years revealed a constant increase in skin thickness (mean 6% per year) and bone density (left hip mean 5% per year, lumbar spine mean 5% per year).

CONCLUSION

In postmenopausal women on long term corticosteroids, skin thickness and bone density were both decreased, but the addition of HRT as add back improved the situation dramatically. Skin thickness and bone density level in women on long term corticosteroids were comparable to that of women who had sustained osteoporotic fractures. It is therefore suggested that HRT be used as add back therapy in postmenopausal women on long term corticosteroid therapy.

Correlation between skin glycosylation and glycaemic control in human diabetes

Glycosylation of human skin has been measured by an adaptation of the thiobarbituric acid reaction on samples obtained mainly at autopsy from normal and diabetic subjects. The mean (+/- 1 SD) glycosylation of skin from 33 normal subjects was 0.072 +/- 0.012 mumol fructosamine/100 mg wet weight tissue compared with 0.127 +/- 0.034 mumol (P less than 0.01) in the 10 diabetic subjects. There was a correlation between mean blood glucose levels in the 6 months before death and skin glycosylation in the diabetics, (r = 0.71, P = 0.025), but no correlation between age, sex, or the presence or absence of diabetic complications and skin glycosylation. Skin glycosylation in samples from four non diabetics was increased from 0.075 +/- 0.015 to 0.126 +/- 0.01 mumol fructosamine/100 mg wet weight tissue (P less than 0.01) after incubation with 50 mmol/l glucose solution for 7 d at 37 degrees C.

Glycosylation of hair: possible measure of chronic hyperglycaemia

To determine whether hair is excessively glycosylated in diabetes mellitus 4 cm hair samples were taken proximally from behind the ear in 50 white non-diabetics and 46 diabetics. Hair glycosylation was assayed by a modification of the thiobarbituric acid reaction. Blood was taken from the diabetics at the same time for measurement of glycosylated haemoglobin concentration. The mean (1 SD) concentration of fructosamine (mumol/100 mg hair) was 0.054 (0.011) for normal hair. Glycosylation was not related to sex, age, or hair colour. The diabetics' hair was more heavily glycosylated (0.097 (0.045] than normal (p less than 0.01) and there was a correlation between hair glycosylation and the concentration of glycosylated haemoglobin in the diabetics (r = 0.71; p less than 0.01). Hair from non-diabetics showed a stable time related increase in glycosylation when incubated with glucose. Glycosylation of hair might provide a stable long term measure of tissue glycosylation, useful in the investigation of microvascular complications of diabetes mellitus.

Werner's syndrome: a review of recent research with an analysis of connective tissue metabolism, growth control of cultured cells, and chromosomal aberrations

Werner's syndrome is a rare, autosomal recessive condition with multiple progeroid features, but it is an imitation of aging rather than accelerated or premature senescence. Somatic chromosome aberrations occur in multiple tissues in vivo and in vitro, and there is an increased incidence of neoplasia. Thus. Werner's syndrome can be classified in the group of chromosome instability syndromes. Recent findings provide additional support for the concept that there is an aberration of connective tissue metabolism in Werner's syndrome, but it is unclear whether this is a primary or secondary manifestation of the underlying genetic defect. Abnormal growth characteristics are observed in cultured skin fibroblast-like cells and this provides another avenue for current research. Identification of the basic genetic defect in Werner's syndrome might clarify our understanding of the normal aging process in general, or might elucidate specific aspects such as the development of neoplasia, atherosclerosis, diabetes, or osteoporosis.